Recent Research Analysts’ Ratings Changes for Medtronic (MDT)

Medtronic (NYSE: MDT) recently received a number of ratings updates from brokerages and research firms:

• 12/16/2025 – Medtronic was given a new $103.00 price target on by analysts at Robert W. Baird.
• 12/15/2025 – Medtronic had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Medtronic had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – Medtronic was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/2/2025 – Medtronic had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Medtronic had its price target raised by analysts at Daiwa Capital Markets from $104.00 to $117.00. They now have a “buy” rating on the stock.
• 11/22/2025 – Medtronic was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/20/2025 – Medtronic had its price target raised by analysts at Barclays PLC from $109.00 to $111.00. They now have an “overweight” rating on the stock.
• 11/20/2025 – Medtronic had its price target raised by analysts at Truist Financial Corporation from $103.00 to $110.00. They now have a “hold” rating on the stock.
• 11/19/2025 – Medtronic was given a new $111.00 price target on by analysts at Sanford C. Bernstein.
• 11/19/2025 – Medtronic was given a new $120.00 price target on by analysts at Leerink Partners. They now have an “outperform” rating on the stock.
• 11/19/2025 – Medtronic had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $110.00 price target on the stock.
• 11/19/2025 – Medtronic was given a new $111.00 price target on by analysts at The Goldman Sachs Group, Inc.. They now have a “neutral” rating on the stock.
• 11/19/2025 – Medtronic was upgraded by analysts at The Goldman Sachs Group, Inc. from a “sell” rating to a “neutral” rating. They now have a $111.00 price target on the stock, up previously from $81.00.
• 11/19/2025 – Medtronic had its price target raised by analysts at Morgan Stanley from $107.00 to $117.00. They now have an “overweight” rating on the stock.
• 11/19/2025 – Medtronic had its price target raised by analysts at Royal Bank Of Canada from $111.00 to $118.00. They now have an “outperform” rating on the stock.
• 11/19/2025 – Medtronic had its price target raised by analysts at UBS Group AG from $95.00 to $102.00. They now have a “neutral” rating on the stock.
• 11/19/2025 – Medtronic had its price target raised by analysts at Wells Fargo & Company from $100.00 to $114.00. They now have an “overweight” rating on the stock.
• 11/19/2025 – Medtronic had its price target raised by analysts at Robert W. Baird from $103.00 to $109.00. They now have a “neutral” rating on the stock.
• 11/14/2025 – Medtronic had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 11/14/2025 – Medtronic had its “neutral” rating reaffirmed by analysts at Piper Sandler.
• 11/13/2025 – Medtronic had its price target raised by analysts at JPMorgan Chase & Co. from $90.00 to $100.00. They now have a “neutral” rating on the stock.
• 11/2/2025 – Medtronic was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 10/31/2025 – Medtronic had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $98.00 price target on the stock.
• 10/25/2025 – Medtronic was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, December 26th. Medtronic’s payout ratio is presently 76.55%.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.